QLF31907

DRUG3 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Advanced Malignant NeoplasmLymphoma, Non-HodgkinMelanomaSolid TumorUrothelial Carcinoma

Phase 1

A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors

RecruitingNCT05150405

Qilu Pharmaceutical Co., Ltd.Lymphoma, Non-Hodgkin, Solid Tumor

Start: 2021-10-19End: 2024-06-01Target: 54Updated: 2024-01-23

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Not yet recruitingNCT06394713

Qilu Pharmaceutical Co., Ltd.Advanced Malignant Neoplasm

Start: 2024-06-15End: 2026-12-15Target: 60Updated: 2024-05-01

Phase 2

Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma

Qilu Pharmaceutical Co., Ltd.Melanoma, Urothelial Carcinoma

Start: 2023-04-24End: 2024-07-31Target: 66Updated: 2023-05-26

Related Papers

Safety and efficacy of a novel PD-L1/4-1BB bispecific antibody QLF31907 in previously-treated patients with advanced melanoma: Results from a phase 2 study.

Journal of Clinical Oncology2026-05-27

A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma.

Journal of Clinical Oncology2024-06-011 citations